Navigating Headwinds: Novo Nordisk's Strategic Pivot in a Competitive Market

Novo Nordisk settles lawsuit with Hims & Hers, turning a rival into a partner for Wegovy/Ozempic distribution, while preparing for 2026 profit decline and Eli Lilly competition.

Danish pharmaceutical giant Novo Nordisk is bracing for a challenging 2026, outlining a dual strategy of aggressive market defense and shareholder returns. Despite forecasting a potential decline in earnings, the company is signaling confidence through substantial share buybacks and a dividend increase, while simultaneously moving to neutralize emerging competitive threats.

A Litigious Dispute Transforms into a Distribution Alliance

In a significant strategic shift, Novo Nordisk has settled its legal battle with U.S. telehealth provider Hims & Hers. The lawsuit, filed in February, accused the platform of selling cheaper, unregulated copycat versions of Novo's weight-loss drug Wegovy. The conflict has now been resolved, paving the way for a commercial partnership.

Under the new agreement, Hims & Hers will become an official distribution channel for the authentic Ozempic and Wegovy medications. In return, the platform will cease marketing its "compounding" imitation products. This maneuver achieves two critical objectives for Novo Nordisk: it mitigates the growing competition from lower-cost alternatives and secures a powerful digital pathway to patients. This channel complements the company's existing physical network of approximately 70,000 U.S. pharmacies.

Mounting Challenges from Rivals and Market Forces

This defensive consolidation comes at a crucial time. Company leadership anticipates a difficult market environment, projecting a currency-adjusted sales and operating profit decline of 5% to 13% for 2026. This outlook is attributed to slowing prescription growth dynamics, intense price pressure in the critical U.S. market, and the expiration of favorable rebate adjustments from the previous year.

A formidable challenge also looms from arch-rival Eli Lilly. The American firm is poised to launch its own oral weight-loss drug, Orforglipron, in the second quarter following anticipated FDA approval. While Novo Nordisk is countering with its own oral version of Wegovy, which currently boasts over 600,000 prescriptions, the market is bracing for a significantly more aggressive price war in the lucrative GLP-1 drug sector.

Financial Measures to Bolster Shareholder Confidence

To reassure investors in light of the subdued annual forecast, the pharmaceutical conglomerate is deploying familiar financial tools. An ongoing share repurchase program, valued at up to 15 billion Danish kroner, aims to support earnings per share by reducing the number of outstanding shares. A tranche of 3.8 billion kroner is allocated for buybacks running until early May. Concurrently, the total dividend for the past fiscal year has been raised by 2.6%.

The market's reception of this combined strategy of market expansion and capital return will be tested imminently. At the Annual General Meeting scheduled for March 26 in Copenhagen, the newly composed Board of Directors must present a detailed plan to investors. The central question will be how the company intends to protect its profit margins within the increasingly competitive GLP-1 market throughout the coming year.